Reports
Reports
Sale
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Philippines Clinical Diagnostics Market Overview
3.1 Philippines Clinical Diagnostics Market Historical Value (2017-2023)
3.2 Philippines Clinical Diagnostics Market Forecast Value (2024-2032)
4 Philippines Clinical Diagnostics Market Dynamics
4.1 Market Drivers and Constraints
4.2 SWOT Analysis
4.2.1 Strengths
4.2.2 Weaknesses
4.2.3 Opportunities
4.2.4 Threats
4.3 Porter’s Five Forces Model
4.3.1 Bargaining Power of Suppliers
4.3.2 Bargaining Power of Buyers
4.3.3 Threat of New Entrants
4.3.4 Threat of Substitutes
4.3.5 Degree of Rivalry
4.4 Key Demand Indicators
4.5 Key Price Indicators
4.6 Industry Events, Initiatives, and Trends
4.7 Value Chain Analysis
5 Philippines Clinical Diagnostics Market Segmentation
5.1 Philippines Clinical Diagnostics Market by Test
5.1.1 Market Overview
5.1.2 Lipid Panel
5.1.3 Liver Panel
5.1.4 Renal Panel
5.1.5 Complete Blood Count
5.1.6 Electrolyte Testing
5.1.7 Infectious Disease Testing
5.1.8 Other Tests
5.2 Philippines Clinical Diagnostics Market by Product
5.2.1 Market Overview
5.2.2 Instruments
5.2.3 Reagents
5.2.4 Other Products
5.3 Philippines Clinical Diagnostics Market by End User
5.3.1 Market Overview
5.3.2 Hospital Laboratory
5.3.3 Diagnostic Laboratory
5.3.4 Point of Care Testing
5.3.5 Other End Users
6 Patent Analysis
6.1 Analysis by Type of Patent
6.2 Analysis by Publication Year
6.3 Analysis by Issuing Authority
6.4 Analysis by Patent Age
6.5 Analysis by CPC Analysis
6.6 Analysis by Patent Valuation
6.7 Analysis by Key Players
7 Grants Analysis
7.1 Analysis by Year
7.2 Analysis by Amount Awarded
7.3 Analysis by Issuing Authority
7.4 Analysis by Grant Application
7.5 Analysis by Funding Institute
7.6 Analysis by NIH Departments
7.7 Analysis by Recipient Organization
8 Funding Analysis
8.1 Analysis by Funding Instances
8.2 Analysis by Type of Funding
8.3 Analysis by Funding Amount
8.4 Analysis by Leading Players
8.5 Analysis by Leading Investors
8.6 Analysis by Geography
9 Partnership and Collaborations Analysis
9.1 Analysis by Partnership Instances
9.2 Analysis by Type of Partnership
9.3 Analysis by Leading Players
9.4 Analysis by Geography
10 Regulatory Framework
10.1 Regulatory Overview
11 Supplier Landscape
11.1 Abbott
11.1.1 Financial Analysis
11.1.2 Product Portfolio
11.1.3 Demographic Reach and Achievements
11.1.4 Mergers and Acquisitions
11.1.5 Certifications
11.2 ARUP Laboratories
11.2.1 Financial Analysis
11.2.2 Product Portfolio
11.2.3 Demographic Reach and Achievements
11.2.4 Mergers and Acquisitions
11.2.5 Certifications
11.3 OPKO Health, Inc.
11.3.1 Financial Analysis
11.3.2 Product Portfolio
11.3.3 Demographic Reach and Achievements
11.3.4 Mergers and Acquisitions
11.3.5 Certifications
11.4 Bioscientia Healthcare GmbH
11.4.1 Financial Analysis
11.4.2 Financial Portfolio
11.4.3 Demographic Reach and Achievements
11.4.4 Mergers and Acquisitions
11.4.5 Certifications
11.5 Charles River Laboratories
11.5.1 Financial Analysis
11.5.2 Product Portfolio
11.5.3 Demographic Reach and Achievements
11.5.4 Mergers and Acquisitions
11.5.5 Certifications
11.6 NeoGenomics Laboratories
11.6.1 Financial Analysis
11.6.2 Product Portfolio
11.6.3 Demographic Reach and Achievements
11.6.4 Mergers and Acquisitions
11.6.5 Certifications
11.7 Genoptix, Inc.
11.7.1 Financial Analysis
11.7.2 Product Portfolio
11.7.3 Demographic Reach and Achievements
11.7.4 Mergers and Acquisitions
11.7.5 Certifications
11.8 Healthscope
11.8.1 Financial Analysis
11.8.2 Product Portfolio
11.8.3 Demographic Reach and Achievements
11.8.4 Mergers and Acquisitions
11.8.5 Certifications
11.9 The Laboratory Glassware Co.
11.9.1 Financial Analysis
11.9.2 Product Portfolio
11.9.3 Demographic Reach and Achievements
11.9.4 Mergers and Acquisitions
11.9.5 Certifications
11.10 Laboratory Corporation of America Holdings
11.10.1 Financial Analysis
11.10.2 Product Portfolio
11.10.3 Demographic Reach and Achievements
11.10.4 Mergers and Acquisitions
11.10.5 Certifications
11.11 Fresenius Medical Care AG and Co. KGaA
11.11.1 Financial Analysis
11.11.2 Product Portfolio
11.11.3 Demographic Reach and Achievements
11.11.4 Mergers and Acquisitions
11.11.5 Certifications
11.12 QIAGEN
11.12.1 Financial Analysis
11.12.2 Product Portfolio
11.12.3 Demographic Reach and Achievements
11.12.4 Mergers and Acquisitions
11.12.5 Certifications
11.13 Quest Diagnostics Incorporated
11.13.1 Financial Analysis
11.13.2 Product Portfolio
11.13.3 Demographic Reach and Achievements
11.13.4 Mergers and Acquisitions
11.13.5 Certifications
11.14 Siemens Healthcare Private Limited
11.14.1 Financial Analysis
11.14.2 Product Portfolio
11.14.3 Demographic Reach and Achievements
11.14.4 Mergers and Acquisitions
11.14.5 Certifications
11.15 Tulip Diagnostics (P) Ltd.
11.15.1 Financial Analysis
11.15.2 Product Portfolio
11.15.3 Demographic Reach and Achievements
11.15.4 Mergers and Acquisitions
11.15.5 Certifications
12 Philippines Clinical Diagnostics Market - Distribution Model (Additional Insight)
12.1 Overview
12.2 Potential Distributors
12.3 Key Parameters for Distribution Partner Assessment
13 Key Opinion Leaders (KOL) Insights (Additional Insight)
14 Company Competitiveness Analysis (Additional Insight)
14.1 Very Small Companies
14.2 Small Companies
14.3 Mid-Sized Companies
14.4 Large Companies
14.5 Very Large Companies
15 Payment Methods (Additional Insight)
15.1 Government Funded
15.2 Private Insurance
15.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
The market is anticipated to grow at a CAGR of 4.8% during the forecast period of 2024-2032, driven by increasing healthcare and research associated investments along with growing prevalence of infectious diseases across the region.
The market demand is driven by the rising emphasis on preventing infectious and fatal chronic diseases via early detection. The increasing integration of modern technologies, such as artificial intelligence and mobile systems, in clinical diagnostics is also fuelling the market demand.
The rising investments focused on improving the healthcare infrastructure is a major market trend. In September 2023, the Consul-General of Japan and Surigao city mayor signed an agreement to grant PHP 3.5 million (USD 62k) to establish mobile x-ray system in one of the city hospitals. Moreover, the government also sanctioned 123 new infrastructure projects worth USD 163 billion.
Based on test, the market is divided into lipid panel, liver panel, renal panel, complete blood count, electrolyte testing, and infectious disease testing, among other tests.
Instruments and reagents, among others are the common technologies available in the market.
Major end users include hospital laboratory, diagnostic laboratory, point of care testing, and others.
Key players involved in the market are Abbott, ARUP Laboratories, OPKO Health, Inc., Bioscientia Healthcare GmbH, Charles River Laboratories, NeoGenomics Laboratories, Genoptix, Inc., Healthscope, The Laboratory Glassware Co., Laboratory Corporation of America Holdings, Fresenius Medical Care AG, and Co. KGaA, QIAGEN, Quest Diagnostics Incorporated, Siemens Healthcare Private Limited, and Tulip Diagnostics (P) Ltd.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.